Some new hope for women with late-stage HER2-positive breast cancer: a new drug shows remarkable results in treating the disease. T-DM1 seeks out HER2 proteins on cancer cells and delivers chemotherapy directly to the cells. It can shrink cancer throughout the body significantly for about a year, giving women their lives back without serious side effects. T-DM1 doesn’t cause the usual hair loss, nausea, and diarrhea. T-DM1 is being fast-tracked for approval by the FDA and is expected to be available to women with advanced HER2-positive cancer by early 2013.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.